Last reviewed · How we verify
durvalumab, tremelimumab, paclitaxel
durvalumab, tremelimumab, paclitaxel is a Small molecule drug developed by Asan Medical Center. It is currently in Phase 1 development.
At a glance
| Generic name | durvalumab, tremelimumab, paclitaxel |
|---|---|
| Sponsor | Asan Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Fatigue
- Nausea
- Abdominal pain
- Vomiting
- Constipation
- Anorexia
- Diarrhea
- Alopecia
- Back pain
- Edema limbs
- Peripheral sensory neuropathy
- Dyspnea
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- durvalumab, tremelimumab, paclitaxel CI brief — competitive landscape report
- durvalumab, tremelimumab, paclitaxel updates RSS · CI watch RSS
- Asan Medical Center portfolio CI
Frequently asked questions about durvalumab, tremelimumab, paclitaxel
What is durvalumab, tremelimumab, paclitaxel?
durvalumab, tremelimumab, paclitaxel is a Small molecule drug developed by Asan Medical Center.
Who makes durvalumab, tremelimumab, paclitaxel?
durvalumab, tremelimumab, paclitaxel is developed by Asan Medical Center (see full Asan Medical Center pipeline at /company/asan-medical-center).
What development phase is durvalumab, tremelimumab, paclitaxel in?
durvalumab, tremelimumab, paclitaxel is in Phase 1.
What are the side effects of durvalumab, tremelimumab, paclitaxel?
Common side effects of durvalumab, tremelimumab, paclitaxel include Fatigue, Nausea, Abdominal pain, Vomiting, Constipation, Anorexia.